Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours

Next Previous
Trial Profile

A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Carboplatin (Primary) ; Datopotamab deruxtecan (Primary) ; Durvalumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Infliximab (Primary) ; Mycophenolate mofetil (Primary) ; Prednisolone (Primary) ; Prednisone (Primary) ; Rilvegostomig (Primary) ; Saruparib (Primary) ; Volrustomig (Primary) ; Antihistamines; Glucocorticoids; Paracetamol
  • Indications Biliary cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Ovarian cancer; Prostate cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TROPION-PanTumor03
  • Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

  • 03 Sep 2024 According to an AstraZeneca media release, a mini-oral presentation at ESMO will highlight first results from the endometrial and ovarian cancer cohorts of the TROPION-PanTumor03 Phase II trial of datopotamab deruxtecan.
  • 09 Aug 2024 Planned number of patients changed from 531 to 582.
  • 24 Apr 2024 Planned number of patients changed from 670 to 531.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top